<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04065932</url>
  </required_header>
  <id_info>
    <org_study_id>IM011-020</org_study_id>
    <nct_id>NCT04065932</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets</brief_title>
  <official_title>A Study to Determine the Pharmacokinetic Profile of BMS-986165 Administered as Various Solid Dispersion Tablet Formulations in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to Determine the Drug Level Profile of Different formulations of BMS-986165 Tablets
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 22, 2019</start_date>
  <completion_date type="Actual">December 10, 2019</completion_date>
  <primary_completion_date type="Actual">December 8, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) for BMS-986165</measure>
    <time_frame>Day 1 of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to time of last quantifiable concentration- AUC(0-T) for BMS- 986165</measure>
    <time_frame>Day 1 of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time- AUC(INF) for BMS-986165</measure>
    <time_frame>Day 1 of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed plasma concentration-(Tmax) for BMS -986165</measure>
    <time_frame>Day 1 of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent plasma elimination half-life- (T-HALF) for BMS-986165</measure>
    <time_frame>Day 1 of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time zero to 24 hours post- (AUC 0-24) for BMS-986165</measure>
    <time_frame>Day 1 of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance -(CL/F) for BMS-986165</measure>
    <time_frame>Day 1 of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration observed at 24 hours-(C24) for BMS-986165</measure>
    <time_frame>Day 1 of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration observed at 12 hours-(C12) for BMS-986165</measure>
    <time_frame>Day 1 of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-serious adverse events(AE's) leading to discontinuation of study therapy.</measure>
    <time_frame>Approximately 16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAE) leading to discontinuation of study therapy.</measure>
    <time_frame>Approximately 16 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs) leading to discontinuation of study therapy.</measure>
    <time_frame>Approximately 16 weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Lupus</condition>
  <arm_group>
    <arm_group_label>BMS-985165-01 prototype formulation 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-986165 Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-985165-01 prototype formulation 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-985165-01 prototype formulation 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-985165-01 prototype formulation 3 or 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-985165-01 prototype formulation 3, 4 or 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986165-01</intervention_name>
    <description>Participants will receive BMS- 986165 -01 in prototype formulation</description>
    <arm_group_label>BMS-985165-01 prototype formulation 1</arm_group_label>
    <arm_group_label>BMS-985165-01 prototype formulation 2</arm_group_label>
    <arm_group_label>BMS-985165-01 prototype formulation 3</arm_group_label>
    <arm_group_label>BMS-985165-01 prototype formulation 3 or 4</arm_group_label>
    <arm_group_label>BMS-985165-01 prototype formulation 3, 4 or 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986165 Tablet</intervention_name>
    <description>Participants will receive BMS-986165 in tablet form.</description>
    <arm_group_label>BMS-986165 Tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine</intervention_name>
    <description>Participants will receive a previously dosed BMS-985165-01 Prototype Tablet at the same dose level following administration of famotidine</description>
    <arm_group_label>BMS-985165-01 prototype formulation 3 or 4</arm_group_label>
    <arm_group_label>BMS-985165-01 prototype formulation 3, 4 or 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Patients must be willing and able to complete all study-specific procedures and visits

          -  Healthy patients, as determined by no clinically significant deviation from normal in
             medical history, physical examination, electrocardiogram, and clinical laboratory
             determinations

          -  Body mass index (BMI) of 18 to 32 kg/m2, inclusive, at screening

          -  Normal renal function at screening

        Exclusion Criteria:

          -  History or presence of chronic bacterial, viral infection, or autoimmune disorder

          -  Active TB requiring treatment or documented latent TB within the previous 3 years

          -  Current or recent (within 3 months of study treatment administration) gastrointestinal
             disease that could affect absorption

          -  WOCBP (women of childbearing potential) must have negative serum or urine pregnancy
             test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Quotient Sciences</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 21, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 22, 2019</study_first_posted>
  <last_update_submitted>December 24, 2019</last_update_submitted>
  <last_update_submitted_qc>December 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BMS-986165</mesh_term>
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

